Logo

AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

Share this

AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

Shots:

  • The P-II DESTINY-Breast01 study involves assessing of Trastuzumab Deruxtecan (DS-8201) in 253 patients with HER2+ unresectable and/or m-breast cancer prior treated with trastuzumab emtansine
  • The P-II DESTINY-Breast01 study result: met its 1EPs; safe & tolerable as in previous trials; supporting the onset of FDA’s BLA submission in H2’19
  • Trastuzumab Deruxtecan (DS-8201) is an ADC- delivers cytotoxic agents to the targeted cancer cell via linker attached to a mAb- currently evaluating in 5 trials for multiple cancer and has received FDA’s BT & MHLW’s Sakigake designation for HER2+ LA/m-breast cancer & adnavced gastric cancer respectively

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions